Articles about Puma Biotechnology
Puma Biotechnology
Puma Biotechnology (PBYI) Price Target Increased by 5.26% to 5.10
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology (NASDAQ:PBYI) Stock Rating Upgraded by StockNews.com - MarketBeat
Puma Biotechnology, Inc.
PBYI / Puma Biotechnology, Inc. - Put/Call Ratio, Options Sentiment, Unusual Options Activity
$16-$32/hr Puma Biotechnology Jobs (NOW HIRING) Dec 2023
Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology, Inc. (NASD:PBYI) Seasonal Chart | Equity Clock
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters
Puma Biotechnology Reports Third Quarter 2022 Financial Results | Business Wire
Puma Biotechnology, Inc. (NASD:PBYI) Seasonal Chart | Equity Clock
Puma Biotechnology, Inc. | CDISC
PBYI Stock Price and Chart — NASDAQ:PBYI — TradingView
Why Puma Biotechnology, Inc. Stock Crashed 37% in March
Puma Biotechnology, Inc.
PBYI Stock Price and Chart — NASDAQ:PBYI — TradingView
